Scarica l'app Stockscreener
1.57
5.42%
-0.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1.66
Aprire:
$1.66
Volume 24 ore:
807.00K
Relative Volume:
0.50
Capitalizzazione di mercato:
$70.53M
Reddito:
-
Utile/perdita netta:
$-97.22M
Rapporto P/E:
-1.1377
EPS:
-1.38
Flusso di cassa netto:
$-82.44M
1 W Prestazione:
+9.03%
1M Prestazione:
-17.37%
6M Prestazione:
-94.09%
1 anno Prestazione:
-92.77%
Intervallo 1D:
$1.56
$1.66
Intervallo di 1 settimana:
$1.37
$1.73
Portata 52W:
$1.15
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Nome
Cassava Sciences Inc
Settore
Industria
Telefono
512-501-2444
Indirizzo
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Confronta SAVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
1.57 | 70.53M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
| 2021-04-27 | Iniziato | B. Riley Securities | Buy |
| 2021-02-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Downgrade | Maxim Group | Buy → Hold |
| 2020-01-10 | Reiterato | Maxim Group | Buy |
Mostra tutto
Cassava Sciences Inc Borsa (SAVA) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
Cassava Sciences (SAVA) Announces Leadership Change Amid Future Strategy Plans - GuruFocus
Cassava Sciences appoints new SVP of Clinical Development By Investing.com - Investing.com South Africa
Cassava Sciences CMO James Kupiec to Retire - marketscreener.com
Cassava's Chief Medical Officer to retire (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences Announces Leadership Changes Amid Strategic Shift - TipRanks
Cassava Sciences appoints new SVP of Clinical Development - Investing.com
Cassava Announces Retirement of Chief Medical Officer, Dr. - GlobeNewswire
Cassava Sciences Pivots Beyond Alzheimer's: New Leadership Eyes Breakthrough in Rare Disease Treatment - Stock Titan
Investigation announced for Long-Term Investors in Cassava - openPR.com
Cassava Sciences, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsSAVA - ACCESS Newswire
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - MSN
SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles By Investing.com - Investing.com South Africa
SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles - Investing.com Australia
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Stockholders to Connect - ACCESS Newswire
SAVA stock touches 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
SAVA stock touches 52-week low at $1.34 amid market challenges - Investing.com Australia
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Yahoo Finance
After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs - Being Patient
Is the Future Bleak for SAVA Stock Following Another Setback? - Nasdaq
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - MSN
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful - MSN
Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - MSN
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug By Reuters - Investing.com
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Zacks Investment Research
Cassava ends Alzheimer’s program after simufilam fails again - The Pharma Letter
Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Yahoo Finance
Cassava Sciences Inc Azioni (SAVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):